語系:
繁體中文
English
說明(常見問題)
圖資館首頁
登入
回首頁
切換:
標籤
|
MARC模式
|
ISBD
Idiopathic pulmonary fibrosisadvance...
~
Aoshiba, Kazutetsu.
Idiopathic pulmonary fibrosisadvances in diagnostic tools and disease management /
紀錄類型:
書目-電子資源 : Monograph/item
正題名/作者:
Idiopathic pulmonary fibrosisedited by Hiroyuki Nakamura, Kazutetsu Aoshiba.
其他題名:
advances in diagnostic tools and disease management /
其他作者:
Nakamura, Hiroyuki.
出版者:
Tokyo :Springer Japan :2016.
面頁冊數:
x, 259 p. :ill., digital ;24 cm.
Contained By:
Springer eBooks
標題:
Pulmonary fibrosis.
電子資源:
http://dx.doi.org/10.1007/978-4-431-55582-7
ISBN:
9784431555827$q(electronic bk.)
Idiopathic pulmonary fibrosisadvances in diagnostic tools and disease management /
Idiopathic pulmonary fibrosis
advances in diagnostic tools and disease management /[electronic resource] :edited by Hiroyuki Nakamura, Kazutetsu Aoshiba. - Tokyo :Springer Japan :2016. - x, 259 p. :ill., digital ;24 cm.
From epidemiology and pathogenesis to disease management, this book reviews our current understanding of and provides up-to-date information of Idiopathic Pulmonary Fibrosis (IPF) A subtype of Idiopathic Interstitial Pneumonias (IIP), IPF is one of the most elusive and intractable respiratory disease to date and its triggering factors remain unclear. However, new developments such as serum markers that are highly specific to IPF (i.e. KL-6, SP-A, and SP-D), the establishment of systematic diagnostic imaging (HRCT) and accumulated reports of treatment using an antifibrotic agent (pirfenidone) are slowly improving our understanding of the disease. Edited by an established authority in the field and written by experts, this book will be valuable to not only to beginning learners but also to physicians, instructors and researchers whose work involves IIPs. With each chapter exploring critical questions, with unresolved issues and future prospects, the book offers a valuable resource for understanding issues such as the newly proposed entity of interstitial pneumonia with emphysema (combined pulmonary fibrosis and emphysema: CPFE) and the mechanism of how so many IP sufferers develop lung cancer.
ISBN: 9784431555827$q(electronic bk.)
Standard No.: 10.1007/978-4-431-55582-7doiSubjects--Topical Terms:
676426
Pulmonary fibrosis.
LC Class. No.: RC776.F5
Dewey Class. No.: 616.24
Idiopathic pulmonary fibrosisadvances in diagnostic tools and disease management /
LDR
:02168nmm a2200301 a 4500
001
481902
003
DE-He213
005
20160727151452.0
006
m d
007
cr nn 008maaau
008
161007s2016 ja s 0 eng d
020
$a
9784431555827$q(electronic bk.)
020
$a
9784431555810$q(paper)
024
7
$a
10.1007/978-4-431-55582-7
$2
doi
035
$a
978-4-431-55582-7
040
$a
GP
$c
GP
041
0
$a
eng
050
4
$a
RC776.F5
072
7
$a
MJL
$2
bicssc
072
7
$a
MED079000
$2
bisacsh
082
0 4
$a
616.24
$2
23
090
$a
RC776.F5
$b
I19 2016
245
0 0
$a
Idiopathic pulmonary fibrosis
$h
[electronic resource] :
$b
advances in diagnostic tools and disease management /
$c
edited by Hiroyuki Nakamura, Kazutetsu Aoshiba.
260
$a
Tokyo :
$b
Springer Japan :
$b
Imprint: Springer,
$c
2016.
300
$a
x, 259 p. :
$b
ill., digital ;
$c
24 cm.
520
$a
From epidemiology and pathogenesis to disease management, this book reviews our current understanding of and provides up-to-date information of Idiopathic Pulmonary Fibrosis (IPF) A subtype of Idiopathic Interstitial Pneumonias (IIP), IPF is one of the most elusive and intractable respiratory disease to date and its triggering factors remain unclear. However, new developments such as serum markers that are highly specific to IPF (i.e. KL-6, SP-A, and SP-D), the establishment of systematic diagnostic imaging (HRCT) and accumulated reports of treatment using an antifibrotic agent (pirfenidone) are slowly improving our understanding of the disease. Edited by an established authority in the field and written by experts, this book will be valuable to not only to beginning learners but also to physicians, instructors and researchers whose work involves IIPs. With each chapter exploring critical questions, with unresolved issues and future prospects, the book offers a valuable resource for understanding issues such as the newly proposed entity of interstitial pneumonia with emphysema (combined pulmonary fibrosis and emphysema: CPFE) and the mechanism of how so many IP sufferers develop lung cancer.
650
0
$a
Pulmonary fibrosis.
$3
676426
650
1 4
$a
Medicine & Public Health.
$3
273799
650
2 4
$a
Pneumology/Respiratory System.
$3
274253
650
2 4
$a
Cytokines and Growth Factors.
$3
379480
700
1
$a
Nakamura, Hiroyuki.
$3
738248
700
1
$a
Aoshiba, Kazutetsu.
$3
738249
710
2
$a
SpringerLink (Online service)
$3
273601
773
0
$t
Springer eBooks
856
4 0
$u
http://dx.doi.org/10.1007/978-4-431-55582-7
950
$a
Medicine (Springer-11650)
筆 0 讀者評論
全部
電子館藏
館藏
1 筆 • 頁數 1 •
1
條碼號
館藏地
館藏流通類別
資料類型
索書號
使用類型
借閱狀態
預約狀態
備註欄
附件
000000121739
電子館藏
1圖書
電子書
EB RC776.F5 I19 2016
一般使用(Normal)
在架
0
1 筆 • 頁數 1 •
1
多媒體
多媒體檔案
http://dx.doi.org/10.1007/978-4-431-55582-7
評論
新增評論
分享你的心得
Export
取書館別
處理中
...
變更密碼
登入